Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors-Reference-Cited by-同舟云学术

Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

Published:2017-02 Issue:2 Volume:46 Page:151-156
ISSN:0885-3177
Container-title:Pancreas
language:en
Short-container-title:

Author:

Sharma Nancy,Naraev Boris G.,Engelman Eric G.,Zimmerman M. Bridget,Bushnell David L.,O'Dorisio Thomas M.,O'Dorisio M. Sue,Menda Yusuf,Müller-Brand Jan,Howe James R.,Halfdanarson Thorvardur R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference32 articles.

1. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches;Oberg;Curr Opin Oncol,2012

2. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes;Hallet;Cancer,2015

3. Surgery for GEP-NETs;Knigge;Best Pract Res Clin Gastroenterol,2012

4. The surgical management of neuroendocrine tumour hepatic metastases;Pathak;Eur J Surg Oncol,2013

5. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies;Mayo;J Am Coll Surg,2013

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety;Seminars in Nuclear Medicine;2024-07

2. Evaluation of a blood miRNA/mRNA signature to follow-up Lu-PRRT therapy for G1/G2 intestinal neuroendocrine tumors;Frontiers in Endocrinology;2024-06-14

3. Current Management of Neuroendocrine Tumour Liver Metastases;Current Oncology Reports;2024-06-13

4. Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects;Zeitschrift für Naturforschung C;2024-05-29

5. Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience;Neuroendocrinology;2024